WaveMan
WaveMan · Company
CLYM · Climb Bio, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CLYM Climb Bio (CLYM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001768446
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
84
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $195.1K priced

What the filings say about CLYM

Insiders, 180 days
-$1.8M net sold
2 sellers · 50% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.5M
1 notice

Climb Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Climb Bio, Inc. insiders sold a net $1.8M of stock across 13 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Thomas Stephen Basil
Director
SELL
2026-09-17 SECtraded 2026-09-15
100,000
$1.4M
-37.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 26, 2026.
  • The trade is 21.4% of the 467,969 shares held after it.
  • No other insider sold within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thomas Stephen Basil sold about $1.4M of CLYM under a 10b5-1 plan on Sep 15, 2026, the largest insider sale at the company on our record; 84 funds added in the latest 13F quarter.
Brennan Aoife
President and CEO
SELL
2026-06-30 SECtraded 2026-06-29
30,902
$407.0K
-33.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 30, 2025.
  • The trade is 35.2% of the 87,731 shares held after it.
  • No other insider sold within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Brennan Aoife sold about $407.0K of CLYM on Jun 29, 2026; 84 funds added in the latest 13F quarter.
Thomas Stephen Basil
Director
SELL
2026-02-27 SECtraded 2026-02-26
16,313
$114.4K
+24.6%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 25, 2026.
  • The trade is 10.5% of the 154,657 shares held after it.
  • No other insider sold within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thomas Stephen Basil sold about $114.4K of CLYM on Feb 26, 2026; 84 funds added in the latest 13F quarter.
Thomas Stephen Basil
Director
SELL
2026-02-27 SECtraded 2026-02-25
33,687
$235.8K
+24.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 13, 2026.
  • The trade is 19.7% of the 170,970 shares held after it.
  • No other insider sold within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thomas Stephen Basil sold about $235.8K of CLYM on Feb 25, 2026; 84 funds added in the latest 13F quarter.
Thomas Stephen Basil
Director
SELL
2026-02-17 SECtraded 2026-02-13
10,000
$58.1K
+60.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 12, 2026.
  • The trade is 4.9% of the 204,657 shares held after it.
  • No other insider sold within 30 days.
  • 84 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thomas Stephen Basil sold about $58.1K of CLYM on Feb 13, 2026; 84 funds added in the latest 13F quarter.
13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 8 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.8M over 180 days
-$1.4M over 90 days
below 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
84 funds bought in last quarter
more than 62% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
25.1% of the float short (float per yahoo 2026-10-26) · 5.6 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CLYM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+342.7%12M
-18%+254%+525%+796%2025-102025-122026-022026-042026-062026-082026-10 2026-09-15 · Thomas Stephen Basil sold $1.4M2026-02-12 · Thomas Stephen Basil sold $470.7K2025-12-11 · Kolchinsky Peter bought $464.6K2026-06-29 · Brennan Aoife sold $407.0K2025-12-12 · Kolchinsky Peter bought $290.2K2026-02-25 · Thomas Stephen Basil sold $235.8K2026-02-26 · Thomas Stephen Basil sold $114.4K2026-02-13 · Thomas Stephen Basil sold $58.1K2026-01-05 · RA Capital Healthcare Fund LP bought $24.9K2026-09-15 · STEPHEN THOMAS filed to sell $1.5M2026-06-30 · AOIFE BRENNAN filed to sell $407.0K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CLYM: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
11,300,939 sh
$147.4M
FMR LLC
6,790,364 sh
$88.5M
UBS Group AG
3,404,866 sh
$44.4M
BRAIDWELL LP
2,797,375 sh
$36.5M
ADAGE CAPITAL PARTNERS GP, L.L.C.
2,506,000 sh
$32.7M

Congress trades in CLYM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CLYM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
STEPHEN THOMAS
Filed 2026-09-15
$1.5M
AOIFE BRENNAN
Filed 2026-06-30
$407.0K

CLYM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Cambria Value and Momentum ETF
$913.4K position · as of 2026-07-31
0.8%
AMG Frontier Small Cap Growth Fund
$667.8K position · as of 2026-07-31
0.7%
Virtus Biotech Clinical Trials Etf
$323.3K position · as of 2026-07-31
0.7%
Ultra-Small Company Fund
$652.0K position · as of 2026-06-30
0.7%
Ultra-Small Company Market Fund
$962.4K position · as of 2026-06-30
0.6%
Fidelity Advisor Biotechnology Fund
$11.9M position · as of 2026-07-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
1
Phase 2
1 active
1
Early Phase 1
0 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.8M sold by insiders over 180 days, 84 funds added last quarter, $1.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CLYM financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-27.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-26.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-30.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$67.9M-$82.0M-$40.3M-$45.1M
Net income-$59.9M-$73.9M-$35.1M-$45.2M
EPS (diluted)-0.88-1.53-1.30-1.72
Operating cash flow-$54.4M-$15.6M-$20.6M-$37.4M
Cash$35.7M$87.2M$93.1M$43.6M
SEC XBRL, fiscal years, as known on 2026-10-28

CLYM Stock Sonar score 4/7 axes

Find similar shapesCompare

CLYM ranks highest on profitability (66th percentile) and institutional and government (62nd), and lowest on risk and compliance (8th), among Pharma & Biotech peers.

Profitability
66
Inputs
  • Return on equity-27.1% · 68 pct, sector of 545
  • Return on assets-26.3% · 63 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-30.4% · 67 pct, sector of 576
Insider conviction
22
Inputs
  • Net Form 4 buying (codes P and S), 180d-$407K · 43 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
62
Inputs
  • Funds adding, latest quarter84 · 62 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
8
Inputs
  • Short interest, % of float+25.1% · 8 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CLYM filings, in plain words

Are Climb Bio insiders buying or selling CLYM?

In the 180 days to 2026-10-28, Climb Bio insiders were net sellers, a net $1.8M across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of CLYM?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $1.5M of stock; the latest, by STEPHEN THOMAS, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-28, Climb Bio insiders were net sellers of CLYM, a net $1.8M across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $1.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies